Oncology Institute, INC Form 4 insider transactions

Karen Marie Johnson, a director at Oncology Institute, acquired 52,000 shares of restricted stock on November 22, 2024.

Mohit Kaushal, a director at Oncology Institute, acquired 56,000 shares of common stock on November 22, 2024, as part of a restricted stock unit grant.

Director Gabriel Ling of Oncology Institute, Inc. acquired 40,000 shares of restricted stock on November 22, 2024.

Director Brad Hively of Oncology Institute, Inc. acquired 44,000 shares of restricted stock units, which will vest at the 2025 annual shareholder meeting.

The CEO of Oncology Institute, Daniel Virnich, sold a portion of his shares to cover tax obligations related to vesting restricted stock units.

The Chief Financial Officer of Oncology Institute, Robert Ross Carter, sold 235 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Yale Podnos, Chief Medical Officer of Oncology Institute, sold shares to cover tax obligations related to vesting restricted stock units.

Yale Podnos, Chief Medical Officer of Oncology Institute, forfeited a total of 28,398 shares due to the company's stock price failing to meet specified targets within the required timeframe.

A director at Oncology Institute, Mark L. Pacala, forfeited a total of 50,620 unvested restricted shares due to the company's stock price failing to meet specific earn-out targets.

Oncology Institute's CEO, Daniel Virnich, forfeited a total of 195,236 unvested restricted shares due to the company's stock price failing to meet specific performance targets.

Havencrest Healthcare Partners, L.P. distributed shares of Oncology Institute, Inc. common stock to its members and limited partners in a pro-rata in-kind distribution.

Director Brad Hively sold 18,121 shares of Oncology Institute, Inc. to cover tax withholding obligations related to the vesting of restricted stock units.

Director Brad Hively of Oncology Institute, Inc. [TOI] sold 19,526 shares of common stock on May 22, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Daniel Virnich, CEO of Oncology Institute, reports the disposition and acquisition of common stock and stock options on May 21, 2024.

Mihir Shah, CFO of Oncology Institute, reports the acquisition of common stock and non-qualified stock options.

Yale Podnos, Chief Medical Officer of Oncology Institute, reports acquisition of stock options and restricted stock units (RSUs) on May 21, 2024.

Jeremy Castle, COO of Oncology Institute, reports the acquisition of stock options and vesting of restricted stock units (RSUs) in a recent SEC Form 4 filing.